New York, New York 10021

  • Lung Cancer


RATIONALE: Drugs used in chemotherapy, such as epothilone D, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well epothilone D works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to platinum-based chemotherapy.

Study summary:

OBJECTIVES: Primary - Determine the antitumor activity of epothilone D, in terms of confirmed objective response rate, in patients with stage IIIB or IV non-small cell lung cancer who failed prior initial platinum-containing chemotherapy. Secondary - Determine the safety of this drug in these patients. - Determine the response duration in patients who achieve complete response or partial response, time to tumor progression, and survival in patients treated with this drug. - Compare the power associated with the estimated treatment effect of this drug in these patients vs standard treatment. - Correlate efficacy and safety with plasma concentrations of this drug and its major metabolites in these patients. OUTLINE: This is a multicenter, open-label study. Patients receive epothilone D IV over 90 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 33-85 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) - Stage IIIB* or IV disease NOTE: *Due to malignant pleural effusion or supraclavicular lymph node involvement only - Previously treated with maximally feasible surgical resection and/or radiotherapy for initial disease - Failed 1 prior platinum-containing chemotherapy regimen for advanced or metastatic disease due to disease progression or treatment toxicity - At least 1 site of unidimensionally measurable disease by physical exam or radiography - No known CNS metastases or leptomeningeal metastases requiring corticosteroids PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-1 Life expectancy - More than 3 months Hematopoietic - Absolute neutrophil count ≥ 1,500/mm^3 - Hemoglobin ≥ 8 g/dL - Platelet count ≥ 75,000/mm^3 Hepatic - AST ≤ 2.5 times upper limit of normal (ULN) (5 times ULN for patients with hepatic metastases) - Alkaline phosphatase ≤ 5 times ULN - Bilirubin ≤ 1.8 mg/dL Renal - Creatinine ≤ 2.0 mg/dL Cardiovascular - No New York Heart Association class III or IV congestive heart failure - No personal or family history of congenital long QT syndrome - No QTc interval > 450 msec (males) or > 470 msec (females) by ECG Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No preexisting neuropathy ≥ grade 2 - No other malignancy within the past 5 years except for the following: - Cured basal cell skin cancer - Carcinoma in situ of the cervix or urinary bladder - Stage T1 or T2 prostate cancer with prostate-specific antigen < 2 ng/mL - No hypersensitivity reaction ≥ grade 3 to prior Cremophor-containing therapy - No infection requiring parenteral or oral anti-infective therapy - No weight loss of ≥ 10% within the past 3 months - No altered mental status or psychiatric illness that would preclude giving informed consent - No other medical condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent granulocyte-macrophage colony-stimulating factor (sargramostim [GM-CSF]) - No concurrent routine prophylactic granulocyte colony-stimulating factor (filgrastim [G-CSF]) Chemotherapy - See Disease Characteristics - At least 3 weeks since prior chemotherapy and recovered Endocrine therapy - See Disease Characteristics Radiotherapy - See Disease Characteristics - At least 3 weeks since prior radiotherapy and recovered Surgery - See Disease Characteristics - At least 3 weeks since prior surgery and recovered Other - Prior adjuvant or neoadjuvant therapy allowed - Prior radiosensitizers allowed - At least 2 weeks since prior gefitinib - More than 3 weeks since prior investigational agents (therapeutic or diagnostic) - No other concurrent investigational agents - No other concurrent anticancer treatment



Primary Contact:

Principal Investigator
Naiyer Rizvi, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.